Image-Guided Atherectomy Device Helps Physicians See Inside Arteries
The Cardiovascular Department at Mills-Peninsula Health Services is one of the first in the United States to offer a new treatment recently cleared by the U.S. Food and Drug Administration (FDA) to provide relief for patients suffering from the painful symptoms of peripheral artery disease, or PAD — a condition caused by a build-up of plaque that blocks blood flow in the arteries to the legs and feet.
Dirk Baumann, M.D. and Stephanie Lin, M.D., vascular surgeons at Mills-Peninsula, are two of the first physicians in the country using Avinger’s Pantheris™ lumivascular atherectomy system, the first-ever, image-guided atherectomy device for the treatment of PAD.
Mills-Peninsula Health Services today announced that it is completing the sale of the Mills-Peninsula Skilled Nursing operations, located at 1609 Trousdale Drive in Burlingame, to Plum Healthcare Group, LLC. The California Department of Public Health granted an operating license to Plum Healthcare Group, and transfer of ownership will take place on June 30. The new entity will be called Peninsula Post-Acute.
“The guiding principle for the sale of our skilled nursing facility has been to ensure quality services will continue to be available in our community,” said Dolores Gomez, Mills-Peninsula Health Services chief operating officer. “This move is part of an ongoing effort to concentrate resources on services our hospital is best positioned to provide, reduce costs and be more affordable to our acute care patients.” Read More about Mills-Peninsula to Sell Skilled Nursing Operations to Plum Healthcare Group
Mills-Peninsula’s Advanced Joint Care and Replacement Center Joins the California Joint Replacement Registry
Mills-Peninsula’s new Advanced Joint Care and Replacement Center, which opened to patients in July 2014, has joined the California Joint Replacement Registry (CJRR), an independent organization that collects and reports patient data about the outcomes of joint replacement procedures. Mills-Peninsula joined the CJRR in an effort to continuously improve quality and satisfaction for our patients who have hip and knee replacements.
Since its opening, the Advanced Joint Care and Replacement Center has registered more than 200 knee and hip replacement patients in the CJRR. “Tracking patient outcomes in the CJRR is truly beneficial to patients and the joint replacement care field as a whole,” said Kyoko Lok, clinical nurse case reviewer in Quality Management at Mills-Peninsula. Read More about Mills-Peninsula’s Advanced Joint Care and Replacement Center Joins the California Joint Replacement Registry
Mills-Peninsula Health Services and the Palo Alto Medical Foundation (PAMF) —not-for-profit affiliates of Sutter Health – are providing $9 million in funding over the next three years to 11 community clinics in Alameda, Santa Clara, Santa Cruz and San Mateo Counties. The community clinics provide health care for free or reduced rates to low-income and uninsured people who may otherwise be unable to access medical care.
“Caring for the community is at the heart of what we do at Mills-Peninsula and the Palo Alto Medical Foundation,” says Jeff Gerard, Regional President, Sutter Health. “We are committed to improving health care throughout the Bay Area. By partnering with these clinics, we will help increase much-needed access to medical care.”
“Our partnership with Mills-Peninsula goes beyond the dollars to truly keep people healthier,” says Sharon Petersen, Samaritan House director of operations. “So many wonderful physicians from Mills-Peninsula help people feel good day to day.”
Sutter Davis Hospital CEO Janet Wagner to Succeed Retiring Bob Merwin
Janet Wagner, chief executive officer of Sutter Davis Hospital, has been named the next CEO for Mills-Peninsula Health Services. She will be only the fourth CEO at Mills-Peninsula in its 60-year history. Wagner succeeds current Mills-Peninsula CEO Bob Merwin who has led the organization for 27 years. Wagner begins her new role on September 29 and will work closely with Merwin to ensure a smooth transition upon his retirement in January 2015.
“I am very proud that we are able to tap talent like Janet Wagner’s from within the Sutter Health family to grow and take on new leadership roles. This is especially important as we continue on the path to become a truly integrated health care organization, linking and strengthening local, regional and system-wide strategies and services to keep our patients at the center of everything we do,” said Jeff Gerard, Sutter Health regional president.
A new treatment that effectively targets cancer cells is offering pain relief, improved quality-of-life and extended survival time for men with late-stage prostate cancer that has spread to the bones.
Mills-Peninsula’s Dorothy E. Schneider Cancer Center has introduced this new cancer treatment, Xofigo (Radium-223 dichloride), for patients with advanced-stage prostate cancer that has metastasized to the bones, but not other organs. Xofigo was approved by the U.S. Food and Drug Administration (FDA) in May 2013 for treatment of metastatic castration-resistant prostate cancer. Mills-Peninsula’s cancer center is among the first in the Bay Area to offer this new treatment.
“This drug has very low toxicity and has the potential to create comfort in men who are suffering, and it may even prolong their lives,” says Stephen Weller, M.D., a Mills-Peninsula radiation oncologist. “It is an important drug — similar to other types of radiation treatment but more effective.”